Agenus to present botensilimab data at late-breaking oral session at asco-gi

Lexington, mass., dec. 21, 2022 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the company will present expanded data on botensilimab in combination with balstilimab at the american society of clinical oncology – gastrointestinal cancers symposium (asco-gi), to be held january 19-21, 2023, in san francisco, ca.
AGEN Ratings Summary
AGEN Quant Ranking